Filing Analysis
Intensity Therapeutics, Inc. announced its financial results for the three and six months ended June 30, 2026. The filing serves as a formal announcement of the release of quarterly earnings data.
📋 Key Facts
- Financial results released for the three and six months ended June 30, 2026.
- Filing date: August 11, 2026.
- Company is an emerging growth company.
Intensity Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Stockholders voted on the election of directors, ratification of the accounting firm, and amendments to stock incentive and employee purchase plans.
🚩 Red Flags
- Low voter turnout: Only 40.74% of outstanding shares were represented, indicating potential shareholder apathy or fragmentation.
📋 Key Facts
- Quorum was established with 1,079,494 shares represented (approximately 40.74% of outstanding shares).
- Dr. Emer Leahy and Lewis H. Bender were elected as Class III directors.
- EisnerAmper LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Stockholders approved increasing the 2021 Stock Incentive Plan by 150,000 shares.
- Stockholders approved increasing the 2024 Employee Stock Purchase Plan by 25,000 shares.
Intensity Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026. The announcement was made through a press release filed under Item 2.02.
📋 Key Facts
- Financial results for the three months ended March 31, 2026, were released on May 7, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The company is an emerging growth company as defined in Rule 405.
- The press release was included as Exhibit 99.1.
Intensity Therapeutics, Inc. reported its financial results for the fiscal year ended December 31, 2025, on March 27, 2026. The disclosure was made via a press release attached to the filing and coincided with the submission of the company's Annual Report on Form 10-K.
📋 Key Facts
- Financial results released for the fiscal year ended December 31, 2025
- Filing date and report date of March 27, 2026
- Item 2.02 (Results of Operations and Financial Condition) triggered
- Press release included as Exhibit 99.1
- Company is an emerging growth company
Intensity Therapeutics has filed a prospectus supplement to increase the capacity of its existing at-the-market (ATM) offering program to $60.0 million. The program, managed by H.C. Wainwright & Co., is intended to provide the company with additional financial flexibility to access capital as needed.
🚩 Red Flags
- Potential for significant equity dilution if the full $60 million capacity is utilized
- ATM offerings can put downward pressure on the stock price as shares are sold into the open market
📋 Key Facts
- Increased ATM offering capacity to an aggregate of $60.0 million
- Sales agent is H.C. Wainwright & Co. LLC
- The original Offering Agreement was dated July 3, 2024
- The company is under no obligation to issue shares and will do so at its discretion
Intensity Therapeutics has regained compliance with Nasdaq's minimum bid price requirement, resolving a deficiency that had been ongoing since June 2025. The company's common stock maintained a closing bid price of at least $1.00 for 10 consecutive business days ending March 4, 2026.
🚩 Red Flags
- Prolonged period of non-compliance lasting approximately nine months (June 2025 to March 2026).
- Historical stock price weakness necessitating a 180-day extension to avoid delisting.
📋 Key Facts
- Received Nasdaq notification on March 5, 2026, confirming compliance with Rule 5550(a)(2).
- Maintained a minimum closing bid price of $1.00 per share from February 19, 2026, through March 4, 2026.
- The original deficiency notice was received on June 6, 2025.
- The company had previously received a 180-day extension on December 4, 2025, which would have expired on June 1, 2026.
Intensity Therapeutics updated its investor presentation to include preliminary, unaudited financial highlights for the fiscal year ended December 31, 2025. The company noted that these figures are subject to final closing procedures and may differ from the final audited financial statements.
📋 Key Facts
- Updated Financial Highlights Slide through December 31, 2025
- Figures are preliminary and unaudited
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- The updated slide was made available on the company's Investor Relations website on March 5, 2026
Intensity Therapeutics, Inc. has announced a 1-for-25 reverse stock split to be effective on February 18, 2026. The move is intended to consolidate shares and maintain compliance with Nasdaq listing requirements.
🚩 Red Flags
- Reverse stock split is a common defensive measure to avoid Nasdaq delisting due to low share price (typically below $1.00)
- Often perceived by the market as a signal of financial distress or lack of organic share price appreciation
📋 Key Facts
- Reverse stock split ratio: 1-for-25
- Effective date/time: February 18, 2026, at 4:01 p.m. ET
- New trading basis: Expected to begin trading on a post-split basis on February 19, 2026
- Fractional shares will be settled in cash based on the closing price on Feb 18, 2026
- The company's ticker symbol 'INTS' and CUSIP (45828J 202) will remain/be updated accordingly
- Adjustments will be made to exercise prices for all outstanding options, warrants, and convertible securities
Intensity Therapeutics received a second notice from Nasdaq granting an additional 180-day compliance period to resolve its minimum bid price deficiency. The company must maintain a $1.00 closing bid price or implement a reverse stock split by June 1, 2026, to avoid delisting.
🚩 Red Flags
- Failure to meet the $1.00 minimum bid price requirement for the initial compliance period.
- Explicit mention of a potential reverse stock split as the primary method to avoid delisting.
- Risk of delisting from Nasdaq if compliance is not met by June 1, 2026.
📋 Key Facts
- Received 'December 2025 Nasdaq Letter' on December 4, 2025.
- Eligible for an additional 180-day compliance period until June 1, 2026.
- Must maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive business days to regain compliance.
- Nasdaq Staff indicated that a reverse stock split is historically the only definitive plan acceptable to resolve this specific deficiency.
- If a reverse split is used, it must be completed no later than 10 business days prior to the June 1, 2026 expiration date.
Intensity Therapeutics, Inc. has filed a prospectus supplement to increase the capacity of its existing at-the-market (ATM) offering program by $30 million. The expansion is intended to provide enhanced financial flexibility and capital access via H.C. Wainwright & Co. LLC.
🚩 Red Flags
- Potential for future dilution of existing shareholders through ATM share issuances.
- The need for increased capital capacity often suggests a desire to preserve cash runway in a pre-revenue biotech context.
📋 Key Facts
- Increased ATM offering capacity to an aggregate of $30 million.
- The offering is conducted under an agreement dated July 3, 2024, with H.C. Wainwright & Co. LLC as the Sales Agent.
- Issuance of shares is at the Company's discretion and subject to market conditions.
- Legal opinion provided by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Intensity Therapeutics, Inc. announced its financial results for the three and nine months ended September 30, 2025. The filing serves as a formal announcement of the release of quarterly earnings data.
📋 Key Facts
- Financial results released for the three and nine months ended September 30, 2025.
- Filing date: November 6, 2025.
- The report includes a press release as Exhibit 99.1.
Intensity Therapeutics, Inc. entered into a securities purchase agreement to conduct a registered direct offering of 5,000,000 shares at $0.80 per share, aiming to raise approximately $4.0 million in gross proceeds.
🚩 Red Flags
- Dilutive offering: Issuance of 5 million new shares will dilute existing shareholders.
- Low share price: The $0.80 pricing is near the Nasdaq minimum bid requirement threshold ($1.00), suggesting potential future reverse split risk if the stock remains depressed.
📋 Key Facts
- Offering size: 5,000,000 shares of common stock.
- Price per share: $0.80.
- Aggregate gross proceeds: Approximately $4.0 million (before fees).
- Placement Agent: A.G.P./Alliance Global Partners (7.0% cash fee + expense reimbursement).
- Expected closing date: On or about November 3, 2025.
- Registration Statement: Filed on July 3, 2024; declared effective July 11, 2024.
Intensity Therapeutics, Inc. held a special meeting of stockholders on October 22, 2025, where shareholders approved a proposal for a reverse stock split with a ratio between 1-for-5 and 1-for-30. The company also received approval to adjourn the meeting if necessary to secure sufficient votes.
🚩 Red Flags
- Approval of a reverse stock split is often used to regain compliance with minimum bid price requirements for exchange listing (Nasdaq).
- The wide range of the potential split (up to 1-for-30) suggests significant uncertainty regarding the required consolidation ratio.
📋 Key Facts
- Special Meeting held on October 22, 2025 via live webcast.
- Quorum reached with 22,869,562 shares (approx. 46.61% of outstanding common stock) represented.
- Proposal 1 (Reverse Stock Split): Approved by 18,333,570 'For' votes vs 4,508,502 'Against' votes.
- The exact reverse split ratio will be determined by the Board of Directors within a range of 1-for-5 to 1-for-30.
- Proposal 2 (Adjournment): Approved with 18,869,741 'For' votes vs 3,893,779 'Against' votes.
Intensity Therapeutics announced a clinical update for its INVINCIBLE-4 study, reporting the first pathological complete response (pCR) in Cohort A. However, patient enrollment has been paused due to localized skin irritation observed in some patients.
🚩 Red Flags
- Clinical trial pause: Enrollment is temporarily halted due to adverse events (localized skin irritation).
📋 Key Facts
- First patient in Cohort A achieved a pathological complete response (pCR) following two doses of INT230-6 and standard of care immunochemotherapy.
- The safety profile is reported as 'favorable' overall, though localized skin irritation near the tumor site was noted in some patients.
- New patient enrollment for Cohort A has been paused to evaluate data and implement adjustments.
Intensity Therapeutics has received confirmation from Nasdaq that it currently complies with the minimum stockholders' equity requirement following a recent $6.6 million ATM offering. However, the company remains under scrutiny and must maintain compliance through its next periodic report to avoid potential delisting.
🚩 Red Flags
- Ongoing risk of delisting if equity levels drop below $2.5 million in future reporting periods.
- Recent reliance on ATM offering suggests capital constraints typical of micro-cap biotech firms.
📋 Key Facts
- Nasdaq confirmed on August 8, 2025, that the Company complies with the Stockholders' Equity Requirement based on June 30, 2025, financials.
- The company raised ~$6.6 million in July 2025 via an At-the-Market (ATM) offering to bolster equity.
- Compliance is contingent upon maintaining requirements through the next periodic report; failure to do so may trigger delisting proceedings.
- The Board of Directors amended the Bylaws on August 12, 2025, reducing the quorum requirement from a majority to one-third of voting power.
Intensity Therapeutics, Inc. released its financial results for the three and six months ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Financial results released for the periods ending June 30, 2025 (three and six months).
- Report date: August 7, 2025.
- The filing includes Exhibit 99.1 containing the press release.
Intensity Therapeutics, Inc. announced the successful completion of an At-the-Market (ATM) offering in July 2025, raising approximately $6.6 million through the sale of common stock.
🚩 Red Flags
- Dilution: The issuance of new common stock increases the total share count (now at 46.0M+), diluting existing shareholders.
📋 Key Facts
- Raised approximately $6.6 million in July 2025 via an At-the-Market (ATM) offering.
- Total shares issued and outstanding as of July 31, 2025: 46,035,081.
- The offering was conducted pursuant to a previously announced ATM program.
Intensity Therapeutics, Inc. held its annual meeting of stockholders on July 17, 2025. The filing reports the results of shareholder votes regarding the election of a director and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held via live webcast on July 17, 2025.
- Quorum reached with 10,989,589 shares (approx. 59.73%) represented.
- Mark A. Goldberg was elected to the Board of Directors (Class II) for a term ending at the 2028 annual meeting.
- EisnerAmper LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Intensity Therapeutics, Inc. completed a common stock offering of approximately 7.68 million shares (including over-allotment) at $0.30 per share, raising roughly $1.9 million in net proceeds. The offering included the issuance of representative warrants to the underwriter.
🚩 Red Flags
- Highly dilutive offering at a low share price ($0.30).
- Significant warrant overhang: Representative's warrants represent 5% of the shares sold.
- Small net proceeds ($1.9M) relative to typical biotech clinical trial costs, suggesting potential ongoing need for frequent capital raises.
📋 Key Facts
- Total shares sold: 6,675,000 firm shares + 1,001,250 option shares = 7,676,250 total shares.
- Offering price: $0.30 per share.
- Net proceeds: Approximately $1.9 million after expenses and commissions.
- Underwriter: ThinkEquity LLC.
- Warrants issued: 383,812 representative warrants at an exercise price of $0.375 (125% of offering price).
- Use of proceeds: Patient enrollment/data readout for INVINCIBLE-4 Study (expected H1 2026), INVINCIBLE-3 Study maintenance, and working capital.
Intensity Therapeutics, Inc. received a deficiency notice from Nasdaq because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company has a 180-day grace period ending December 3, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice/Non-compliance with minimum bid price requirement
- Potential for mandatory reverse stock split to regain compliance
- Risk of delisting from Nasdaq Capital Market if deficiency is not cured by Dec 3, 2025
📋 Key Facts
- Received Nasdaq deficiency notice on June 6, 2025.
- Failure to meet Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)).
- Compliance period: 180 days, expiring December 3, 2025.
- Compliance can be achieved if the stock closes at or above $1.00 for 10 consecutive business days during the grace period.
- The company may need to effect a reverse stock split to meet additional requirements if it seeks a second compliance period.
Intensity Therapeutics, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The company has until July 3, 2025, to submit a compliance plan.
🚩 Red Flags
- Delisting notice (Nasdaq non-compliance)
- Failure to maintain minimum stockholders' equity requirement
- Potential for delisting if a compliance plan is rejected or not met
📋 Key Facts
- Received notice of non-compliance on May 19, 2025.
- Non-compliance is due to failure to meet the minimum stockholders' equity requirement per Nasdaq Listing Rule 5550(b)(1).
- The deficiency was identified based on the Form 10-Q for the period ended March 31, 2025.
- The company has until July 3, 2025, to submit a compliance plan to Nasdaq.
- If the plan is accepted, the company may receive an extension of up to 180 days to regain compliance.
Intensity Therapeutics, Inc. filed an 8-K to announce its financial results for the three months ended March 31, 2025.
📋 Key Facts
- Report date: May 13, 2025
- Reporting period: Three months ended March 31, 2025
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Intensity Therapeutics, Inc. has commenced a best efforts public offering of common stock and warrants to raise approximately $1.9 million in net proceeds. The offering is priced at $0.75 per share/warrant unit, significantly below the exercise price of the accompanying warrants.
🚩 Red Flags
- Highly dilutive offering structure involving a large number of warrants.
- Low net proceeds ($1.9M) relative to the scale of clinical studies mentioned, suggesting potential liquidity constraints.
- Pricing at $0.75 is significantly lower than the warrant exercise price of $0.85, indicating a discounted issuance.
- The company has agreed to restrictions on issuing 'Variable Rate Transactions' for 60 days, often a sign of avoiding predatory financing.
📋 Key Facts
- Offering size: 3,133,333 shares of Common Stock and 6,266,666 total warrants (Series B-1 and B-2).
- Combined offering price: $0.75 per share and accompanying Warrants.
- Warrant exercise price: $0.85 per share.
- Expected net proceeds: Approximately $1.9 million after fees and expenses.
- Use of proceeds: Enrollment in INVINCIBLE-4 Study, treatment for existing patients in INVINCIBLE-3 Study, working capital, and general corporate purposes.
- Placement Agents: A.G.P./Alliance Global Partners (Lead) and Brookline Capital Markets.
- Agent compensation: 7.0% cash fee plus reimbursement of expenses.
Intensity Therapeutics, Inc. filed an 8-K to furnish a corporate presentation dated Q2 2025 under Item 7.01 (Regulation FD Disclosure). The filing is intended for use in meetings with investors and analysts.
📋 Key Facts
- The company posted a corporate presentation dated Q2 2025 as Exhibit 99.1.
- The disclosure was made pursuant to Item 7.01 (Regulation FD Disclosure).
- The filing is intended for use in meetings with investors, analysts, collaborators, or vendors.
Intensity Therapeutics, Inc. released its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the annual earnings release via press release.
📋 Key Facts
- Financial results for the year ended December 31, 2024, were released on March 13, 2025.
- The company is an emerging growth company.
- Results are accompanied by a press release (Exhibit 99.1).
Intensity Therapeutics, Inc. entered into a Securities Purchase Agreement for a registered direct offering of 1,237,113 shares at $2.425 per share, totaling approximately $3.0 million in gross proceeds. The deal includes the issuance of warrants to purchase additional shares and involves multiple placement agents.
🚩 Red Flags
- Dilutive warrant component: Issuance of warrants at $2.95 represents potential future dilution for existing shareholders.
- Small capital raise: The $3.0 million gross proceeds is relatively small, suggesting a need for frequent micro-cap financing to sustain operations.
📋 Key Facts
- Registered direct offering of 1,237,113 common shares at $2.425 per share.
- Aggregate gross proceeds of approximately $3.0 million (before fees).
- Concurrent private placement of warrants to purchase up to 1,237,113 shares at an exercise price of $2.95 per share.
- Warrants are exercisable six months from issuance and expire in five and a half years.
- Placement agents include A.G.P./Alliance Global Partners (lead) and Brookline Capital Markets.
- The offering is expected to close on or about November 22, 2024.
Intensity Therapeutics, Inc. released its financial results for the three and nine months ended September 30, 2024 via a press release.
📋 Key Facts
- Financial results released on November 13, 2024.
- Reporting period covers the three and nine months ended September 30, 2024.
- The filing is an announcement of earnings/financial condition under Item 2.02.
Intensity Therapeutics, Inc. announced the grant of stock options to its Chief Financial Officer and Principal Accounting Officer on October 21, 2024.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Grant Date: October 21, 2024.
- Joseph Talamo (CFO) granted options for 427,379 shares of common stock.
- John Wesolowski (Principal Accounting Officer and Controller) granted options for 70,028 shares of common stock.
- Exercise price is $3.44 per share (fair market value on Grant Date).
- Vesting schedule: Five equal annual installments beginning on the Grant Date.
Intensity Therapeutics, Inc. released its quarterly financial results for the three and six months ended June 30, 2024.
📋 Key Facts
- Financial results were released on August 8, 2024.
- Reporting period covers the three and six months ended June 30, 2024.
- The filing is an announcement of earnings/financial condition under Item 2.02.
Intensity Therapeutics, Inc. held its annual meeting of stockholders on July 17, 2024, where shareholders approved the company's 2024 Employee Stock Purchase Plan (ESPP). The meeting also resulted in the election of two directors and the ratification of EisnerAmper LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on July 17, 2024, via live webcast.
- Quorum reached with 8,522,632 shares (approx. 62.15% of outstanding voting shares) represented.
- Proposal 1: Daniel Donovan and Thomas I. H. Dubin were elected to the Board of Directors.
- Proposal 2: The 2024 Employee Stock Purchase Plan (ESPP) was approved by shareholders.
- Proposal 3: EisnerAmper LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
Intensity Therapeutics, Inc. entered into an At-The-Market (ATM) offering agreement with H.C. Wainwright & Co., LLC to facilitate the sale of up to $15 million in common stock.
🚩 Red Flags
- Potential for immediate share dilution as the company can sell stock into the market at prevailing prices.
📋 Key Facts
- Entered into Sales Agreement with H.C. Wainwright & Co., LLC on July 3, 2024.
- Maximum aggregate sale amount: $15,000,000 of common stock.
- Wainwright will receive a commission of 3.0% of the gross sales price.
- The offering is conducted via an S-3 shelf registration statement filed on July 3, 2024.
- The company has no obligation to sell any shares and may suspend or terminate the agreement at its discretion.
Intensity Therapeutics, Inc. announced the removal of James Ahlers as an officer and executive officer effective May 21, 2024. The company stated the move is due to a reduction in his scope of responsibilities rather than any disagreement regarding operations or policies.
🚩 Red Flags
- Removal of an officer can sometimes signal internal restructuring or friction, though the filing explicitly denies disagreement.
📋 Key Facts
- James Ahlers removed as an officer and 'executive officer' effective May 21, 2024.
- Ahlers will continue to provide senior corporate finance consulting through Danforth Advisors LLC via an existing agreement.
- The company explicitly states the removal is not due to any disagreement regarding operations, policies, or practices.
- The change is attributed solely to a 'reduced scope of responsibilities'.
Intensity Therapeutics, Inc. has appointed Thomas I. H. Dubin to its Board of Directors and Audit Committee to rectify a Nasdaq compliance deficiency regarding audit committee composition.
🚩 Red Flags
- Nasdaq non-compliance notice received on April 18, 2024, due to audit committee composition deficiency.
- Recent resignation of Audit Committee member Daniel Donovan (April 12, 2024).
📋 Key Facts
- Thomas I. H. Dubin appointed to the Board as a Class I director effective May 14, 2024.
- Mr. Dubin appointed to the Audit Committee to restore compliance with Nasdaq Listing Rule 5605(c)(2)(A).
- The appointment follows the resignation of Daniel Donovan from the Audit Committee on April 12, 2024.
- Board size increased from four to five directors.
- Mr. Dubin granted 50,000 stock options with an exercise price of $4.42 per share, vesting in four equal installments.
Intensity Therapeutics entered into a collaboration agreement with The Swiss Group for Cancer Research (SAKK) to conduct the Phase 2 portion of its INVINCIBLE-4 clinical study in Europe. The company will provide up to $3.0 million in funding and supply INT230-6 for testing in women with triple negative breast cancer.
🚩 Red Flags
- The company is providing $3.0 million in funding, which represents a cash outflow for a micro-cap biotech.
📋 Key Facts
- Collaboration agreement signed on May 6, 2024, with SAKK.
- Scope: Phase 2 portion of the INVINCIBLE-4 Study (INT230-6 + standard of care vs. standard of care alone).
- Target Indication: Neoadjuvant triple negative breast cancer in Europe.
- Financial Commitment: Company to provide up to approximately $3.0 million in funding and supply INT230-6.
- Indemnification: SAKK will indemnify the Company for claims arising from SAKK's duties; Company remains liable for manufacturing/distribution issues.
Intensity Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Three months ended March 31, 2024
- Filing date: May 9, 2024
- The company is classified as an 'emerging growth company'
- Financial results were released via press release (Exhibit 99.1)
Intensity Therapeutics received a notice from Nasdaq regarding non-compliance with audit committee composition requirements following the resignation of Daniel Donovan from the Audit Committee. The company has been granted a cure period to appoint a new independent director to the committee to avoid delisting.
🚩 Red Flags
- Delisting notice/non-compliance with Nasdaq listing rules
- Audit committee composition deficiency (only 2 members instead of required 3)
- Potential for delisting if compliance is not regained by the deadline
📋 Key Facts
- Daniel Donovan resigned from the Audit Committee on April 12, 2024, but remains on the Board and serves on the Compensation and Nominating/Governance Committees.
- The Audit Committee currently has only two members, failing to meet Nasdaq Listing Rule 5605 requirement of at least three independent members.
- Nasdaq issued a non-compliance letter on April 18, 2024.
- Cure period expires either at the next annual stockholders' meeting (if before Oct 9, 2024) or by April 14, 2025.
- The company intends to appoint a new Board member to the Audit Committee within the cure period.
Intensity Therapeutics, Inc. released its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of year-end earnings and is accompanied by an updated Annual Report (Form 10-K).
📋 Key Facts
- Financial results for the year ended December 31, 2023, were released on March 14, 2024.
- The filing includes a press release as Exhibit 99.1.
- An Annual Report (Form 10-K) was filed concurrently on March 14, 2024.
Intensity Therapeutics, Inc. announced the adoption of a new Incentive Compensation Plan designed to reward employees and executives based on individual and company-wide performance milestones.
🚩 Red Flags
- Retroactive effectiveness (backdated to Oct 1, 2023) can sometimes be used to smooth or manipulate compensation expenses in prior periods, though it is common in startup/biotech environments for administrative reasons.
📋 Key Facts
- The Board approved an 'Incentive Compensation Plan' on February 6, 2024.
- The plan is retroactively effective as of October 1, 2023.
- Eligibility includes all salaried employees and executive officers.
- Compensation is cash-based and tied to both individual performance objectives and company milestones.